Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function-Reference-Cited by-同舟云学术

Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function

Published:2010-01 Issue:2-3 Volume:626 Page:193-199
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Rojas Camilo,Thomas Ajit G.,Alt Jesse,Stathis Marigo,Zhang Jie,Rubenstein Edward B.,Sebastiani Silvia,Cantoreggi Sergio,Slusher Barbara S.

Publisher

Elsevier BV

Subject

Pharmacology

Reference26 articles.

1. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy;Aapro;Ann. Oncol.,2006

2. Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors;Bonhaus;J. Neurochem.,1995

3. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy;Decker;J. Support. Oncol.,2006

4. The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit;Dubin;J. Biol. Chem.,1999

5. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron;Eisenberg;Cancer,2003

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adequate antiemetic treatment in patients receiving antitumor drug therapy;Head and Neck Tumors (HNT);2024-08-03

2. Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis;Frontiers in Oncology;2024-07-26

3. Comparison of the ED50 of prophylactic butorphanol in preventing morphine-induced pruritus with or without palonosetron: a prospective, double-blinded, randomized dose–response trial using an up-down sequential allocation method;Annals of Medicine;2023-12-12

4. Netupitant/palonosetron (NEPA; Akynzeo®) combination in prevention of the nausea and vomiting in patients with breast cancer receiving anthracyclinbased chemotherapy;Tumors of female reproductive system;2023-10-27

5. Possibilities of prevention of nausea during cytostatic therapy: literature review and clinical cases;Meditsinskiy sovet = Medical Council;2023-07-27